Takeda ending discovery, preclinical work in AAV gene therapy, rare hematology
Takeda told employees recently it is ending discovery and preclinical work in AAV gene therapy as well as research and preclinical work on rare hematology, a spokesperson confirmed in an emailed statement to Endpoints News.
The move will not impact the existing clinical development pipeline or commercial products, the spokesperson said, noting the number of employees impacted is yet to be determined as they might be redeployed to other R&D areas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.